Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553085 | 0.88 | TDP1 (0.40) | TDP1MAPTCA9CA12CA1 | |
| SCHEMBL3121038 | 0.88 | CA9 (0.45) | MAPTCA9PDE4BPDE4APDE4C | |
| SCHEMBL7551170 | 0.85 | TDP1 (0.38) | TDP1MAPTCA9CA12CA1 | |
| SCHEMBL6610448 | 0.84 | KDM4E (0.35) | MAPTPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6954801 | 0.80 | PDE4B (0.55) | TDP1MAPTPDE4BPDE4APDE4C | |
| SCHEMBL6610918 | 0.77 | MAPT (0.52) | MAPTALDH1A1KDM4EL3MBTL1HPGD | |
| SCHEMBL6950190 | 0.77 | PDE4D (0.67) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2171527 | 0.77 | NQO2 (0.44) | MAPTCA9PDE4BALDH1A1KDM4E | |
| SCHEMBL7551167 | 0.76 | TDP1 (0.39) | TDP1MAPTCA9CA12CA1 | |
| SCHEMBL1554410 | 0.76 | NPC1 (0.39) | MAPTCA9CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261605-B1 | BENZOXAZOLE DERIVATIVES AS TNF AND PDE IV INHIBITORS | DARWIN DISCOVERY LTD (GB) | 2004-11-10 | — | — | EP | claimed |
| EP-1261605-A1 | BENZOXAZOLE DERIVATIVES AS TNF AND PDE IV INHIBITORS | Darwin Discovery Limited (GB) | 2002-12-04 | — | — | EP | claimed |
| US-6403791-B1 | TREATMENT OF INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES IN HUMANS OR ANIMALS | DARWIN DISCOVERY, LTD. (GB) | 2002-06-11 | — | — | US | claimed |
| WO-2001058896-A1 | BENZOXAZOLE DERIVATIVES AS TNF AND PDE IV INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 2001-08-16 | — | — | WO | claimed |
| EP-1261605-B1 | BENZOXAZOLE DERIVATIVES AS TNF AND PDE IV INHIBITORS | DARWIN DISCOVERY LTD (GB) | 2004-11-10 | — | — | EP | disclosed |
| EP-0944616-B1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| EP-1261605-A1 | BENZOXAZOLE DERIVATIVES AS TNF AND PDE IV INHIBITORS | Darwin Discovery Limited (GB) | 2002-12-04 | — | — | EP | disclosed |
| US-20020094987-A1 | Bicyclic aryl carboxamides and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-07-18 | — | — | US | disclosed |
| US-6403791-B1 | TREATMENT OF INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES IN HUMANS OR ANIMALS | DARWIN DISCOVERY, LTD. (GB) | 2002-06-11 | — | — | US | disclosed |
| US-6353010-B1 | ENZYME INHIBITORS TUMOR NECROSIS FACTOR AND PHOSPHODIESTERASE FOR ANTIINFLAMMATORY AGENTS | DARWIN DISCOVERY, LTD. (GB) | 2002-03-05 | — | — | US | disclosed |
| WO-2001058896-A1 | BENZOXAZOLE DERIVATIVES AS TNF AND PDE IV INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 2001-08-16 | — | — | WO | disclosed |
| EP-0944616-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998022460-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094987-A1 | Bicyclic aryl carboxamides and their therapeutic use | PDE3B, PDE3A, PDE2A | TDP1 109/4885MAPT 4233/4885CA9 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.